miRNAs orchestration of adrenocortical carcinoma - Particular emphasis on diagnosis, progression and drug resistance

Pathol Res Pract. 2023 Aug:248:154665. doi: 10.1016/j.prp.2023.154665. Epub 2023 Jul 4.

Abstract

Adrenocortical carcinoma (ACC) is an uncommon aggressive endocrine malignancy that is nonetheless associated with significant mortality and morbidity rates because of endocrine and oncological consequences. Recent genome-wide investigations of ACC have advanced our understanding of the disease, but substantial obstacles remain to overcome regarding diagnosis and prognosis. MicroRNAs (miRNAs, miRs) play a crucial role in the development and metastasis of a wide range of carcinomas by regulating the expression of their target genes through various mechanisms causing translational repression or messenger RNA (mRNA) degradation. Along with miRNAs in the adrenocortical cancerous tissue, circulating miRNAs are considered barely invasive diagnostic or prognostic biomarkers of ACC. miRNAs may serve as treatment targets that expand the rather-limited therapeutic repertoire in the field of ACC. Patients with advanced ACC still have a poor prognosis when using the available treatments, despite a substantial improvement in understanding of the illness over the previous few decades. Accordingly, in this review, we provide a crucial overview of the recent studies in ACC-associated miRNAs regarding their diagnostic, prognostic, and potential therapeutic relevance.

Keywords: ACC; Adrenocortical carcinoma; Diagnosis; Drug resistance; MiRNA; Prognosis.

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Neoplasms* / diagnosis
  • Adrenal Cortex Neoplasms* / genetics
  • Adrenocortical Carcinoma* / diagnosis
  • Adrenocortical Carcinoma* / genetics
  • Drug Resistance
  • Humans
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Prognosis

Substances

  • MicroRNAs